Aqualung Therapeutics Corporation
Biotechnology, 1790 E River Rd, Tucson, Arizona, 85718, United States, 1-10 Employees
Phone Number: 31********
Who is AQUALUNG THERAPEUTICS CORPORATION
Aqualung Therapeutics (ALT) is developing multi-pronged strategies to address the development of severe lung inflammation which is essential to the severity and outcomes of acute and chro...
Read More
-
Headquarters: 1790 E River Rd, Tucson, Arizona, 85718, United States
-
Date Founded: 2010
-
Employees: 1-10
-
Revenue: Under $1 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 325414 |
Show More
Does something look wrong? Fix it. | View contact records from AQUALUNG THERAPEUTICS CORPORATION
AQUALUNG THERAPEUTICS CORPORATION Org Chart and Mapping
Email
Phone
Similar Companies to AQUALUNG THERAPEUTICS CORPORATION
Seal Rock Therapeutics
-
1-10
-
$ 1 Million to 5 Million
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding AQUALUNG THERAPEUTICS CORPORATION
Answer: AQUALUNG THERAPEUTICS CORPORATION's headquarters are located at 1790 E River Rd, Tucson, Arizona, 85718, United States
Answer: AQUALUNG THERAPEUTICS CORPORATION's phone number is 31********
Answer: AQUALUNG THERAPEUTICS CORPORATION's official website is https://aqualungtherapeutics.com
Answer: AQUALUNG THERAPEUTICS CORPORATION's revenue is Under $1 Million
Answer: AQUALUNG THERAPEUTICS CORPORATION's SIC: 2836
Answer: AQUALUNG THERAPEUTICS CORPORATION's NAICS: 325414
Answer: AQUALUNG THERAPEUTICS CORPORATION has 1-10 employees
Answer: AQUALUNG THERAPEUTICS CORPORATION is in Biotechnology
Answer: AQUALUNG THERAPEUTICS CORPORATION top competitors include: Seal Rock Therapeutics
Answer: AQUALUNG THERAPEUTICS CORPORATION contact info: Phone number: 31******** Website: https://aqualungtherapeutics.com
Answer: Aqualung Therapeutics (ALT) is developing multi-pronged strategies to address the development of severe lung inflammation which is essential to the severity and outcomes of acute and chronic lung disorders such as acute lung injury, ventilator-induced lung injury (VILI), idiopathic pulmonary fibrosis, and pulmonary hypertension. Effective FDA-approved drugs are either currently unavailable or extraordinarily modest in their ability to modify disease progression. No drug is currently available that is preventive or curative. Aqualungs strategies, which include deployment of a human monoclonal antibody which targets a novel inflammatory mediator (nicotinamide phosphoribosyltransferase or NAMPT) will address the unmet need for novel, effective therapies for VILI, IPF, and pulmonary hypertension.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month